News Focus
News Focus
icon url

McMagyar

12/04/16 11:55 AM

#81937 RE: Gernee20 #81933

This is a good point as well. The adcs pretest scores were the same for both groups; 70 . which would lead one to believe same level of impairment to start.
I don't think Donezipil rejection normally quite that high.. but can't be ruled out as factoring into 7. Aricept Naive doesn't necessarily mean never tried Aricept.
Ariana has probably already saved Anavex 3-6 months and millions of $$
As I don't think there is anyway the good Dr drops Combination without
Insurmountable data. A decision by the way, that will have to be justified next week. How will the good Dr justify such a decision?
With Data!
The real question is..does the Stock Market, Anavex, SEC, Market Makers,
Authority, Institutional buyers, FDA, Media, all knowing that the Short Cabal is so effective preying on new Shareholders, do any/some/ all of these groups have any responsibility for HOW this data is released to the Public as news?
We all want the company to do well, but the Fuerstein:/Fool/Street / market Makers machine is well oiled.
In my opinion it is not reasonable to make a breakthrough announcement and not provide some level of..
Honesty?
icon url

frrol

12/04/16 12:54 PM

#81951 RE: Gernee20 #81933

They're likely correlated, but not the exact same sub pops for several reasons, one of which you stated. Mathematically speaking they have to be fairly significant shared sets because of their respective results: you can't get the same divergence from sample population trend without the overlap. (As an aside, this is not driven by the small sample size; the effect is n-independent.) The exact magnitude of the overlap is the only thing that can't be pinned down without the underlying data, but from a statistician's eye it is about 50% at lowest. And anything above 50% means the disentanglement of the correlation and it's covariance has to be done eventually if we think these variables are valid (hence Ariana, plus the bigger Phase 2/3 will help; this is where the sample size n will matter). I don't know if the company will share that kind of granularity. They may at 52 weeks. They may also talk a little bit more about the top responders (e.g. the artist and pianist) and to which subset(s) they belong. I'm watching for that, but not expecting it.